Intervet/Schering-Plough launches canine ear infection drug

Animal Health Supplier News

Intervet/Schering-Plough has launched a next-generation ear infection treatment for canines that combines the benefits of three different agents.

Posatex Otic Suspension is a seven-day treatment for sufferers of severe otitis externa available in 7.5mg, 15mg and 30g specifications and functions by combating the yeast and bacteria infections that cause the disease.

It contains the active ingredients orbifloxacin, mometasone furoate monohydrate and posaconazole, offering a combination of antifungal, antibiotic and anti-inflammation benefits.

Allan Weingarten, director of pharmaceutical research at the animal health firm and Posatex research and development project leader, said this will provide a convenient new treatment for a "nightmare disease".

He added: "We feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers."

Last month, Intervet/Schering-Plough announced that it is sponsoring the Equine Business Management Strategies scheme, a programme of courses which provide business advice to veterinarians.

See all the latest jobs in Animal Health
Return to news

Tags